Congestive heart failure If-channel inhibitor: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Created page with "== 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (DO NOT EDIT) <ref name="pmid23747642">{{cite journal| author=Yancy CW,...")
 
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
__NOTOC__
{{SI}}
{{CMG}} {{AE}} {{Mitra}}
==Overview==
==I<sub>f</sub>-channel inhibitor==
===Indications===
===Background===
===Dosing===
== 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (DO NOT EDIT) <ref name="pmid23747642">{{cite journal| author=Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE et al.| title=2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=J Am Coll Cardiol | year= 2013 | volume=  | issue=  | pages=  | pmid=23747642 | doi=10.1016/j.jacc.2013.05.019 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23747642  }} </ref><ref name="pmid19324967">Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19324967 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.] ''Circulation'' 119 (14):1977-2016. [http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192064 DOI:10.1161/CIRCULATIONAHA.109.192064] PMID:[http://pubmed.gov/19324967 19324967]</ref><ref name="pmid28461007">{{cite journal| author=Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al.| title=2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. | journal=J Am Coll Cardiol | year= 2017 | volume= 70 | issue= 6 | pages= 776-803 | pmid=28461007 | doi=10.1016/j.jacc.2017.04.025 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28461007  }} </ref>==
== 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (DO NOT EDIT) <ref name="pmid23747642">{{cite journal| author=Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE et al.| title=2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=J Am Coll Cardiol | year= 2013 | volume=  | issue=  | pages=  | pmid=23747642 | doi=10.1016/j.jacc.2013.05.019 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23747642  }} </ref><ref name="pmid19324967">Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=19324967 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation.] ''Circulation'' 119 (14):1977-2016. [http://dx.doi.org/10.1161/CIRCULATIONAHA.109.192064 DOI:10.1161/CIRCULATIONAHA.109.192064] PMID:[http://pubmed.gov/19324967 19324967]</ref><ref name="pmid28461007">{{cite journal| author=Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM et al.| title=2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. | journal=J Am Coll Cardiol | year= 2017 | volume= 70 | issue= 6 | pages= 776-803 | pmid=28461007 | doi=10.1016/j.jacc.2017.04.025 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28461007  }} </ref>==


{|class="wikitable" style="width:80%"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Drugs known to adversely affect the clinical status of patients with current or prior symptoms of [[heart failure]] and reduced [[left ventricular ejection fraction]] ([[LVEF]]) should be avoided or withdrawn whenever possible (e.g., [[NSAID|nonsteroidal anti-inflammatory drugs]], most [[Antiarrhythmic agent|antiarrhythmic drugs]], and most [[Calcium channel blocker|calcium channel blocking drugs]].<ref name="pmid9605782">{{cite journal |author=Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A |title=NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics |journal=[[Archives of Internal Medicine]] |volume=158 |issue=10 |pages=1108–12 |year=1998 |month=May |pmid=9605782 |doi= |url=http://archinte.ama-assn.org/cgi/pmidlookup?view=long&pmid=9605782 |accessdate=2012-04-05}}</ref><ref name="pmid2703968">{{cite journal |author=Herchuelz A, Derenne F, Deger F, Juvent M, Van Ganse E, Staroukine M, Verniory A, Boeynaems JM, Douchamps J |title=Interaction between nonsteroidal anti-inflammatory drugs and loop diuretics: modulation by sodium balance |journal=[[The Journal of Pharmacology and Experimental Therapeutics]] |volume=248 |issue=3 |pages=1175–81 |year=1989 |month=March |pmid=2703968 |doi= |url=http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=2703968 |accessdate=2012-04-05}}</ref><ref name="pmid1529943">{{cite journal |author=Gottlieb SS, Robinson S, Krichten CM, Fisher ML |title=Renal response to indomethacin in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy |journal=[[The American Journal of Cardiology]] |volume=70 |issue=9 |pages=890–3 |year=1992 |month=October |pmid=1529943 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0002-9149(92)90733-F |accessdate=2012-04-05}}</ref><ref name="pmid1655327">{{cite journal |author=Bank AJ, Kubo SH, Rector TS, Heifetz SM, Williams RE |title=Local forearm vasodilation with intra-arterial administration of enalaprilat in humans |journal=[[Clinical Pharmacology and Therapeutics]] |volume=50 |issue=3 |pages=314–21 |year=1991 |month=September |pmid=1655327 |doi= |url= |accessdate=2012-04-05}}</ref><ref name="pmid2473403">{{cite journal |author= |title=Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators |journal=[[The New England Journal of Medicine]] |volume=321 |issue=6 |pages=406–12 |year=1989 |month=August |pmid=2473403 |doi=10.1056/NEJM198908103210629 |url=http://www.nejm.org/doi/abs/10.1056/NEJM198908103210629?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed |accessdate=2012-04-05}}</ref><ref name="pmid1377359">{{cite journal |author= |title=Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators |journal=[[The New England Journal of Medicine]] |volume=327 |issue=4 |pages=227–33 |year=1992 |month=July |pmid=1377359 |doi=10.1056/NEJM199207233270403 |url=http://dx.doi.org/10.1056/NEJM199207233270403 |accessdate=2012-04-05}}</ref><ref name="pmid2476016">{{cite journal |author=Pratt CM, Eaton T, Francis M, Woolbert S, Mahmarian J, Roberts R, Young JB |title=The inverse relationship between baseline left ventricular ejection fraction and outcome of antiarrhythmic therapy: a dangerous imbalance in the risk-benefit ratio |journal=[[American Heart Journal]] |volume=118 |issue=3 |pages=433–40 |year=1989 |month=September |pmid=2476016 |doi= |url=http://linkinghub.elsevier.com/retrieve/pii/0002-8703(89)90254-8 |accessdate=2012-04-05}}</ref> ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])'' <nowiki>"</nowiki>
|}


{|class="wikitable" style="width:80%"
{|class="wikitable" style="width:80%"

Latest revision as of 18:13, 18 September 2021

WikiDoc Resources for Congestive heart failure If-channel inhibitor

Articles

Most recent articles on Congestive heart failure If-channel inhibitor

Most cited articles on Congestive heart failure If-channel inhibitor

Review articles on Congestive heart failure If-channel inhibitor

Articles on Congestive heart failure If-channel inhibitor in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Congestive heart failure If-channel inhibitor

Images of Congestive heart failure If-channel inhibitor

Photos of Congestive heart failure If-channel inhibitor

Podcasts & MP3s on Congestive heart failure If-channel inhibitor

Videos on Congestive heart failure If-channel inhibitor

Evidence Based Medicine

Cochrane Collaboration on Congestive heart failure If-channel inhibitor

Bandolier on Congestive heart failure If-channel inhibitor

TRIP on Congestive heart failure If-channel inhibitor

Clinical Trials

Ongoing Trials on Congestive heart failure If-channel inhibitor at Clinical Trials.gov

Trial results on Congestive heart failure If-channel inhibitor

Clinical Trials on Congestive heart failure If-channel inhibitor at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Congestive heart failure If-channel inhibitor

NICE Guidance on Congestive heart failure If-channel inhibitor

NHS PRODIGY Guidance

FDA on Congestive heart failure If-channel inhibitor

CDC on Congestive heart failure If-channel inhibitor

Books

Books on Congestive heart failure If-channel inhibitor

News

Congestive heart failure If-channel inhibitor in the news

Be alerted to news on Congestive heart failure If-channel inhibitor

News trends on Congestive heart failure If-channel inhibitor

Commentary

Blogs on Congestive heart failure If-channel inhibitor

Definitions

Definitions of Congestive heart failure If-channel inhibitor

Patient Resources / Community

Patient resources on Congestive heart failure If-channel inhibitor

Discussion groups on Congestive heart failure If-channel inhibitor

Patient Handouts on Congestive heart failure If-channel inhibitor

Directions to Hospitals Treating Congestive heart failure If-channel inhibitor

Risk calculators and risk factors for Congestive heart failure If-channel inhibitor

Healthcare Provider Resources

Symptoms of Congestive heart failure If-channel inhibitor

Causes & Risk Factors for Congestive heart failure If-channel inhibitor

Diagnostic studies for Congestive heart failure If-channel inhibitor

Treatment of Congestive heart failure If-channel inhibitor

Continuing Medical Education (CME)

CME Programs on Congestive heart failure If-channel inhibitor

International

Congestive heart failure If-channel inhibitor en Espanol

Congestive heart failure If-channel inhibitor en Francais

Business

Congestive heart failure If-channel inhibitor in the Marketplace

Patents on Congestive heart failure If-channel inhibitor

Experimental / Informatics

List of terms related to Congestive heart failure If-channel inhibitor

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mitra Chitsazan, M.D.[2]


Overview

If-channel inhibitor

Indications

Background

Dosing

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure (DO NOT EDIT) [1][2][3]

Class IIa

1. Ivabradine can be beneficial to reduce HF hospitalization for patients with symptomatic (NYHA class II-III) stable chronic HFrEF (LVEF ≤ 35%) who are receiving GDEM, including a beta blocker at maximum tolerated dose, and who are in sinus rhythm with a heart rate of 70 bpm or greater at rest. (Class IIa, Level of Evidence: B-R)

  1. ↑ Yancy CW, Jessup M, Bozkurt B, Masoudi FA, Butler J, McBride PE; et al. (2013). "2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". J Am Coll Cardiol. doi:10.1016/j.jacc.2013.05.019. PMID 23747642.
  2. ↑ Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (14):1977-2016. DOI:10.1161/CIRCULATIONAHA.109.192064 PMID:19324967
  3. ↑ Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM; et al. (2017). "2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America". J Am Coll Cardiol. 70 (6): 776–803. doi:10.1016/j.jacc.2017.04.025. PMID 28461007.
Retrieved from "https://www.wikidoc.org/index.php?title=Congestive_heart_failure_If-channel_inhibitor&oldid=1714255"